Judah Frommer
Stock Analyst at Morgan Stanley
(4.10)
# 478
Out of 5,154 analysts
184
Total ratings
62.14%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $8.46 | +100.95% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $173.85 | +15.62% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $13.90 | +101.44% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $26.91 | +26.35% | 1 | Feb 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $109.60 | +32.30% | 4 | Jan 9, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $24.40 | -22.13% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $26.69 | +34.88% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $13.01 | +46.04% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $19.97 | +30.20% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $29.00 | +48.28% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $32.74 | -32.80% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $8.35 | -28.14% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.50 | -7.42% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.73 | +86.87% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.37 | +26.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.38 | +2,809.09% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.29 | +295.14% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $34.05 | -32.44% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $61.95 | -19.29% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $15.84 | +790.15% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.48 | +158.62% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $29.63 | -25.75% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.86 | +44.03% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $8.24 | -2.91% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $71.59 | -35.75% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.68 | +161.19% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $11.77 | +367.29% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $142.76 | -67.78% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $87.83 | -44.21% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $996.41 | -62.87% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $89.87 | -65.51% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $85.04 | -10.63% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $145.72 | +24.90% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $114.90 | -6.88% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $107.45 | -11.58% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.40 | +3.45% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $216.27 | -46.36% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $97.26 | -60.93% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $78.06 | -71.82% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $73.67 | -52.49% | 9 | Apr 29, 2020 |
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $8.46
Upside: +100.95%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $173.85
Upside: +15.62%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $13.90
Upside: +101.44%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $26.91
Upside: +26.35%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $109.60
Upside: +32.30%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $24.40
Upside: -22.13%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $26.69
Upside: +34.88%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $13.01
Upside: +46.04%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $19.97
Upside: +30.20%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $29.00
Upside: +48.28%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $32.74
Upside: -32.80%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.35
Upside: -28.14%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.50
Upside: -7.42%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.73
Upside: +86.87%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.37
Upside: +26.58%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.38
Upside: +2,809.09%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $3.29
Upside: +295.14%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $34.05
Upside: -32.44%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $61.95
Upside: -19.29%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $15.84
Upside: +790.15%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.48
Upside: +158.62%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $29.63
Upside: -25.75%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.86
Upside: +44.03%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $8.24
Upside: -2.91%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $71.59
Upside: -35.75%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.68
Upside: +161.19%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $11.77
Upside: +367.29%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $142.76
Upside: -67.78%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $87.83
Upside: -44.21%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $996.41
Upside: -62.87%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $89.87
Upside: -65.51%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $85.04
Upside: -10.63%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $145.72
Upside: +24.90%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $114.90
Upside: -6.88%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $107.45
Upside: -11.58%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.40
Upside: +3.45%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $216.27
Upside: -46.36%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $97.26
Upside: -60.93%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $78.06
Upside: -71.82%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $73.67
Upside: -52.49%